Summary
Scientists have discovered two enzymes, PDIA1 and PDIA5, that help prostate cancer cells resist treatment. Blocking these enzymes can potentially lead to more effective treatments, especially for advanced prostate cancer. The discovery may also enhance existing drugs and is currently showing positive results in lab studies.
Key Facts
- Scientists identified enzymes PDIA1 and PDIA5 as key to prostate cancer cell growth and survival.
- Blocking these enzymes causes instability in the androgen receptor (AR), a protein that fuels cancer growth.
- This process has led to cancer cell death and tumor reduction in lab cell and animal studies.
- Prostate cancer is the second-leading cause of cancer death in American men.
- Researchers found combining enzyme-blocking drugs with the drug enzalutamide improved treatment results.
- The enzymes help cancer cells manage stress and maintain energy, making them targets for treatment.
- Current drugs targeting these enzymes require further development for safety and effectiveness in humans.
